Advertisement

Model of Acute Injury to Study Neuroprotection

  • Michal Schwartz
  • Jonathan Kipnis
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 399)

Abstract

A major causative factor in the paralysis that often follows an acute injury to the central nervous system (CNS) is the paradoxical inability of the CNS to tolerate its own mechanism of self-repair. The dismal result is often a wider spread of damage (part of the inevitable “secondary” or “delayed” degeneration) rather than contribution toward a cure. Ever since the phenomenon of posttraumatic damage spread in the CNS was first recognized, neuroscientists have attempted to identify the players in this destructive process and have sought ways to neutralize or bypass them with the object of rescuing any neurons that are still viable. This approach is collectively termed neuroprotection. In this chapter, we present a view of experimental paradigms used to study neuroprotection.

Key Words

Neuroprotection CNS degeneration partial injuries protective autoimmunity 

References

  1. 1.
    Schwartz, M., Moalem, G., Leibowitz-Amit, R., and Cohen, I. R. (1999) Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci 22, 295–299.CrossRefPubMedGoogle Scholar
  2. 2.
    Villoslada, P., and Genain, C. P. (2004) Role of nerve growth factor and other trophic factors in brain inflammation. Prog Brain Res 146, 403–414.CrossRefPubMedGoogle Scholar
  3. 3.
    Pachter, J. S., de Vries, H. E., and Fabry, Z. (2003) The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 62, 593–604.PubMedGoogle Scholar
  4. 4.
    Neumann, H. (2000) The immunological microenvironment in the CNS: implications on neuronal cell death and survival. J Neural Transm Suppl 59, 59–68.PubMedGoogle Scholar
  5. 5.
    Hailer, N. P., Heppner, F. L., Haas, D., and Nitsch, R. (1998) Astrocytic factors deactivate antigen presenting cells that invade the central nervous system. Brain Pathol 8, 459–474.CrossRefPubMedGoogle Scholar
  6. 6.
    Hatterer, E., Davoust, N., Didier-Bazes, M., Vuaillat, C., Malcus, C., Belin, M. F., and Nataf, S. (2006) How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 107, 806–812.CrossRefPubMedGoogle Scholar
  7. 7.
    Lotan, M., and Schwartz, M. (1994) Cross talk between the immune system and the nervous system in response to injury: implications for regeneration. FASEB J 8, 1026–1033.PubMedGoogle Scholar
  8. 8.
    Lotan, M., Solomon, A., Ben-Bassat, S., and Schwartz, M. (1994) Cytokines modulate the inflammatory response and change permissiveness to neuronal adhesion in injured mammalian central nervous system. Exp Neurol 126, 284–290.CrossRefPubMedGoogle Scholar
  9. 9.
    Broadwell, R. D., Charlton, H. M., Ebert, P., Hickey, W. F., Villegas, J. C., and Wolf, A. L. (1990) Angiogenesis and the blood-brain barrier in solid and dissociated cell grafts within the CNS. Prog Brain Res 82, 95–101.CrossRefPubMedGoogle Scholar
  10. 10.
    Broadwell, R. D., Baker, B. J., Ebert, P. S., and Hickey, W. F. (1994) Allografts of CNS tissue possess a blood-brain barrier: III. Neuropathological, methodological, and immunological considerations. Microsc Res Tech 27, 471–494.CrossRefPubMedGoogle Scholar
  11. 11.
    Cserr, H. F., Harling-Berg, C. J., and Knopf, P. M. (1992) Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol 2, 269–276.CrossRefPubMedGoogle Scholar
  12. 12.
    Cserr, H. F., and Knopf, P. M. (1992) Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 13, 507–512.CrossRefPubMedGoogle Scholar
  13. 13.
    Flugel, A., Berkowicz, T., Ritter, T., Labeur, M., Jenne, D. E., Li, Z., Ellwart, J. W., Willem, M., Lassmann, H., and Wekerle, H. (2001) Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 14, 547–560.CrossRefPubMedGoogle Scholar
  14. 14.
    Hickey, W. F. (1999) Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol 11, 125–137.CrossRefPubMedGoogle Scholar
  15. 15.
    Griffin, D., Levine, B., Tyor, W., Ubol, S., and Despres, P. (1997) The role of antibody in recovery from alphavirus encephalitis. Immunol Rev 159, 155–161.CrossRefPubMedGoogle Scholar
  16. 16.
    Griffin, D. E., and Hardwick, J. M. (1997) Regulators of apoptosis on the road to persistent alphavirus infection. Annu Rev Microbiol 51, 565–592.CrossRefPubMedGoogle Scholar
  17. 17.
    Czech, K. A., Ryan, J. W., Sagen, J., and Pappas, G. D. (1997) The influence of xenotransplant immunogenicity and immunosuppression on host MHC expression in the rat CNS. Exp Neurol 147, 66–83.CrossRefPubMedGoogle Scholar
  18. 18.
    Moalem, G., Monsonego, A., Shani, Y., Cohen, I. R., and Schwartz, M. (1999) Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J 13, 1207–1217.PubMedGoogle Scholar
  19. 19.
    Yoles, E., and Schwartz, M. (1998) Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol 153, 1–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Yurkewicz, L., Weaver, J., Bullock, M. R., and Marshall, L. F. (2005) The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma 22, 1428–1443.CrossRefPubMedGoogle Scholar
  21. 21.
    Belli, A., Sen, J., Petzold, A., Russo, S., Kitchen, N., Smith, M., Tavazzi, B., Vagnozzi, R., Signoretti, S., Amorini, A. M., Bellia, F., and Lazzarino, G. (2006) Extracellular N-acetylaspartate depletion in traumatic brain injury. J Neurochem 96, 861–869.CrossRefPubMedGoogle Scholar
  22. 22.
    Matute, C., Domercq, M., and Sanchez-Gomez, M. V. (2006) Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 53, 212–224.CrossRefPubMedGoogle Scholar
  23. 23.
    Xu, G. Y., Hughes, M. G., Zhang, L., Cain, L., and McAdoo, D. J. (2005) Administration of glutamate into the spinal cord at extracellular concentrations reached post-injury causes functional impairments. Neurosci Lett 384, 271–276.CrossRefPubMedGoogle Scholar
  24. 24.
    McAdoo, D. J., Hughes, M. G., Nie, L., Shah, B., Clifton, C., Fullwood, S., and Hulsebosch, C. E. (2005) The effect of glutamate receptor blockers on glutamate release following spinal cord injury. Lack of evidence for an ongoing feedback cascade of damage → glutamate release → damage → glutamate release → etc. Brain Res 1038, 92–99.CrossRefPubMedGoogle Scholar
  25. 25.
    Parsons, C. G., Danysz, W., and Quack, G. (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11, 523–569.CrossRefPubMedGoogle Scholar
  26. 26.
    Rosin, C., Bates, T. E., and Skaper, S. D. (2004) Excitatory amino acid induced oligodendrocyte cell death in vitro: receptor-dependent and-independent mechanisms. J Neurochem 90, 1173–1185.CrossRefPubMedGoogle Scholar
  27. 27.
    Sargsyan, S. A., Monk, P. N., and Shaw, P. J. (2005) Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 51, 241–253.CrossRefPubMedGoogle Scholar
  28. 28.
    Kim, S. U., and de Vellis, J. (2005) Microglia in health and disease. J Neurosci Res 81, 302–313.CrossRefPubMedGoogle Scholar
  29. 29.
    Croxford, J. L., and Miller, S. D. (2003) Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest 111, 1231–1240.PubMedGoogle Scholar
  30. 30.
    Stieg, P. E., Sathi, S., Warach, S., Le, D. A., and Lipton, S. A. (1999) Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur J Pharmacol 375, 115–120.CrossRefPubMedGoogle Scholar
  31. 31.
    Nagafuji, T., Sugiyama, M., Matsui, T., and Koide, T. (1993) A narrow therapeutical window of a nitric oxide synthase inhibitor against transient ischemic brain injury. Eur J Pharmacol 248, 325–328.PubMedGoogle Scholar
  32. 32.
    Moalem, G., Leibowitz-Amit, R., Yoles, E., Mor, F., Cohen, I. R., and Schwartz, M. (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5, 49–55.CrossRefPubMedGoogle Scholar
  33. 33.
    Popovich, P. G., Yu, J. Y., and Whitacre, C. C. (1997) Spinal cord neuropathology in rat experimental autoimmune encephalomyelitis: modulation by oral administration of myelin basic protein. J Neuropathol Exp Neurol 56, 1323–1338.CrossRefPubMedGoogle Scholar
  34. 34.
    Rapalino, O., Lazarov-Spiegler, O., Agranov, E., Velan, G. J., Yoles, E., Fraidakis, M., Solomon, A., Gepstein, R., Katz, A., Belkin, M., Hadani, M., and Schwartz, M. (1998) Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 4, 814–821.CrossRefPubMedGoogle Scholar
  35. 35.
    Assia, E., Rosner, M., Belkin, M., Solomon, A., and Schwartz, M. (1989) Temporal parameters of low energy laser irradiation for optimal delay of post-traumatic degeneration of rat optic nerve. Brain Res 476, 205–212.CrossRefPubMedGoogle Scholar
  36. 36.
    Rosner, M., Caplan, M., Cohen, S., Duvdevani, R., Solomon, A., Assia, E., Belkin, M., and Schwartz, M. (1993) Dose and temporal parameters in delaying injured optic nerve degeneration by low-energy laser irradiation. Lasers Surg Med 13, 611–617.CrossRefPubMedGoogle Scholar
  37. 37.
    Duvdevani, R., Lavie, V., Segel, L., and Schwartz, M. (1993) A new method for expressing axonal size: rat optic nerve analysis. J Electron Microsc (Tokyo) 42, 412–414.Google Scholar
  38. 38.
    Schwartz, M., Belkin, M., Yoles, E., and Solomon, A. (1996) Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J Glaucoma 5, 427–432.PubMedGoogle Scholar
  39. 39.
    Hauben, E., Agranov, E., Gothilf, A., Nevo, U., Cohen, A., Smirnov, I., Steinman, L., and Schwartz, M. (2001) Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest 108, 591–599.PubMedGoogle Scholar
  40. 40.
    Yoles, E., and Schwartz, M. (1998) Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol 116, 906–910.PubMedGoogle Scholar
  41. 41.
    Schwartz, M., and Cohen, I. R. (2000) Autoimmunity can benefit self-maintenance. Immunol Today 21, 265–268.CrossRefPubMedGoogle Scholar
  42. 42.
    Yoles, E., Belkin, M., and Schwartz, M. (1996) HU-211, a nonpsychotropic cannabinoid, produces short-and long-term neuroprotection after optic nerve axotomy. J Neurotrauma 13, 49–57.CrossRefPubMedGoogle Scholar
  43. 43.
    Kipnis, J., Yoles, E., Porat, Z., Cohen, A., Mor, F., Sela, M., Cohen, I. R., and Schwartz, M. (2000) T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 97, 7446–7451.CrossRefPubMedGoogle Scholar
  44. 44.
    Moalem, G., Yoles, E., Leibowitz-Amit, R., Muller-Gilor, S., Mor, F., Cohen, I. R., and Schwartz, M. (2000) Autoimmune T cells retard the loss of function in injured rat optic nerves. J Neuroimmunol 106, 189–197.CrossRefPubMedGoogle Scholar
  45. 45.
    Levkovitch-Verbin, H., Harris-Cerruti, C., Groner, Y., Wheeler, L. A., Schwartz, M., and Yoles, E. (2000) RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 41, 4169–4174.PubMedGoogle Scholar
  46. 46.
    Fisher, J., Levkovitch-Verbin, H., Schori, H., Yoles, E., Butovsky, O., Kaye, J. F., Ben-Nun, A., and Schwartz, M. (2001) Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. J Neurosci 21, 136–142.PubMedGoogle Scholar
  47. 47.
    Fritzsch, B., and Wilm, C. (1990) Dextran amines in neuronal tracing. Trends Neurosci 13, 14CrossRefPubMedGoogle Scholar
  48. 48.
    Linden, R., and Perry, V. H. (1983) Massive retinotectal projection in rats. Brain Res 272, 145–149.CrossRefPubMedGoogle Scholar
  49. 49.
    Schori, H., Kipnis, J., Yoles, E., WoldeMussie, E., Ruiz, G., Wheeler, L. A., and Schwartz, M. (2001) Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA 98, 3398–3403.CrossRefPubMedGoogle Scholar
  50. 50.
    Schori, H., Robenshtok, E., Schwartz, M., and Hourvitz, A. (2005) Postintoxication vaccination for protection of neurons against the toxicity of nerve agents. Toxicol Sci 87, 163–168.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Michal Schwartz
    • 1
  • Jonathan Kipnis
    • 1
    • 2
  1. 1.Department of NeurobiologyThe Weizmann Institute of ScienceRehovotIsrael
  2. 2.Department of Pharmacology and Experimental Neuroscience and Department of Ophthalmology and Visual SciencesUniversity of Nebraska Medical CenterOmaha

Personalised recommendations